Skip to main content
Erschienen in: Pharmaceutical Medicine 1/2008

01.01.2008 | Review Article

Improving Drug Delivery in Paediatric Medicine

verfasst von: Julia Krause, Dr Jörg Breitkreutz

Erschienen in: Pharmaceutical Medicine | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

A major challenge in drug development is paediatric drug delivery; however, the problems associated with drug administration in this population are manifold. Because of the highly heterogeneous nature of the patient group, ranging from newborns to adolescents, there is a need to use suitable excipients and dosage forms for different age groups and suitable delivery devices for certain formulations. So far, there is a lack of suitable and safe drug formulations for children, especially for the very young and seriously ill. This review provides an overview of current advances in the field of paediatric drug delivery and the challenges that still need to be overcome. With the new EU legislation, which will enforce paediatric clinical trials and drug development, there will be an increased need for more research in to novel paediatric dosage forms. There is also the basic need to further investigate the suitability of dosage forms for different age groups. Current advances in paediatric drug development include interesting new drug delivery concepts such as fast-dissolving drug formulations, including buccal films and wafers, and multiparticulate dosage forms. Parenteral administration is likely to remain the first choice for children in the neonatal period and for emergency cases. Alternative routes of administration also under investigation include transdermal, pulmonary and nasal drug delivery systems. A few products are already available on the market, but others are still under development and will need further investigation and clinical proof.
Fußnoten
1
1The use of trade names is for product identification purposes only and does not imply endorsement
 
Literatur
1.
Zurück zum Zitat Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacologydrug disposition, action, and therapy in infants and children. New Engl J Med 2003; 349: 1157–67PubMedCrossRef Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacologydrug disposition, action, and therapy in infants and children. New Engl J Med 2003; 349: 1157–67PubMedCrossRef
2.
Zurück zum Zitat Rakhmanina NY, van den Anker J. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 2006; 58: 4–14PubMedCrossRef Rakhmanina NY, van den Anker J. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 2006; 58: 4–14PubMedCrossRef
3.
5.
Zurück zum Zitat Schirm E, Tobi H, Vries TW, et al. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 2003; 92: 1486–9PubMedCrossRef Schirm E, Tobi H, Vries TW, et al. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 2003; 92: 1486–9PubMedCrossRef
6.
Zurück zum Zitat Breitkreutz J, Wessel T, Boos J. Dosage forms for peroral drug administration to children. Paediatr Perinat Drug Ther 1999; 3: 25–33 Breitkreutz J, Wessel T, Boos J. Dosage forms for peroral drug administration to children. Paediatr Perinat Drug Ther 1999; 3: 25–33
7.
Zurück zum Zitat Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007; 4 (1): 37–45PubMedCrossRef Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007; 4 (1): 37–45PubMedCrossRef
8.
Zurück zum Zitat MacDonald MG, Getson PR, Glasgow AM, et al. Propylene glycol: increased incidence of seizures in low birth weight infants. Pediatrics 1987; 79 (4): 622–5PubMed MacDonald MG, Getson PR, Glasgow AM, et al. Propylene glycol: increased incidence of seizures in low birth weight infants. Pediatrics 1987; 79 (4): 622–5PubMed
9.
Zurück zum Zitat Glover ML, Reed MD. Propylene glycol: the safe diluent that continues to cause harm. Pharmacotherapy 1996; 16 (4): 690–3PubMed Glover ML, Reed MD. Propylene glycol: the safe diluent that continues to cause harm. Pharmacotherapy 1996; 16 (4): 690–3PubMed
10.
Zurück zum Zitat McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 2007; 370 (9598): 1560–7PubMedCrossRef McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 2007; 370 (9598): 1560–7PubMedCrossRef
12.
Zurück zum Zitat O’Brien K, Selanikio J, Hecdivert C, et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA 1998; 279: 1175–80PubMedCrossRef O’Brien K, Selanikio J, Hecdivert C, et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA 1998; 279: 1175–80PubMedCrossRef
13.
Zurück zum Zitat Zeine C. Impurities in drug products [in German]. Pharm Ind 2007; 69 (5): 624–8 Zeine C. Impurities in drug products [in German]. Pharm Ind 2007; 69 (5): 624–8
14.
Zurück zum Zitat Breitkreutz J. Child-appropriate drug preparations for peroral administration [in German; habilitation thesis]. Münster: University of Münster, 2004 Breitkreutz J. Child-appropriate drug preparations for peroral administration [in German; habilitation thesis]. Münster: University of Münster, 2004
16.
Zurück zum Zitat Standing JF, Khaki ZF, Wong ICK. Poor formulation information in published pediatric drug trials. Pediatrics 2005 Oct; 116 (4): 559–62CrossRef Standing JF, Khaki ZF, Wong ICK. Poor formulation information in published pediatric drug trials. Pediatrics 2005 Oct; 116 (4): 559–62CrossRef
17.
Zurück zum Zitat Matsui D. Assessing the palatability of medications in children. Paediatr Perinat Drug Ther 2007; 8 (2): 55–60CrossRef Matsui D. Assessing the palatability of medications in children. Paediatr Perinat Drug Ther 2007; 8 (2): 55–60CrossRef
18.
Zurück zum Zitat Zheng JY, Keeney MP. Taste masking analysis in pharmaceutical formulation development using an electronic tongue. Int J Pharm 2006 Jan; 310: 118–24PubMedCrossRef Zheng JY, Keeney MP. Taste masking analysis in pharmaceutical formulation development using an electronic tongue. Int J Pharm 2006 Jan; 310: 118–24PubMedCrossRef
19.
Zurück zum Zitat Grießmann K, Breitkreutz J, Schubert-Zsilavecz M, et al. Dosing accuracy of measuring devices provided with antibiotic oral suspensions. Paediatr Perinat Drug Ther 2007; 8 (2): 61–70CrossRef Grießmann K, Breitkreutz J, Schubert-Zsilavecz M, et al. Dosing accuracy of measuring devices provided with antibiotic oral suspensions. Paediatr Perinat Drug Ther 2007; 8 (2): 61–70CrossRef
20.
Zurück zum Zitat Lennartz P, Mielck JB. Minitabletting: improving the compactability of paraceta- mol powder mixtures. Int J Pharm 1998 Jun; 173: 75–85CrossRef Lennartz P, Mielck JB. Minitabletting: improving the compactability of paraceta- mol powder mixtures. Int J Pharm 1998 Jun; 173: 75–85CrossRef
21.
Zurück zum Zitat Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50: 375–82PubMedCrossRef Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50: 375–82PubMedCrossRef
22.
Zurück zum Zitat Mishra R, Amin A. Quick API delivery. Pharm Technol Eur 2007; 10: 35–9 Mishra R, Amin A. Quick API delivery. Pharm Technol Eur 2007; 10: 35–9
23.
Zurück zum Zitat Aurora J, Pathak V. Oral disintegrating dosage forms: an overview. Drug Deliv Technol 2005; 5: 50–4 Aurora J, Pathak V. Oral disintegrating dosage forms: an overview. Drug Deliv Technol 2005; 5: 50–4
24.
Zurück zum Zitat Cassidy JP, Landzert NM, Quadros E. Controlled buccal delivery of buprenorphine. J Control Rel 1993; 25: 21–9CrossRef Cassidy JP, Landzert NM, Quadros E. Controlled buccal delivery of buprenorphine. J Control Rel 1993; 25: 21–9CrossRef
25.
Zurück zum Zitat Bénès L, Claustrat B, Horrière F et al. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. J Pharm Sci 1997; 86: 1115–9PubMedCrossRef Bénès L, Claustrat B, Horrière F et al. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. J Pharm Sci 1997; 86: 1115–9PubMedCrossRef
26.
Zurück zum Zitat Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Rev 1997; 25: 47–58CrossRef Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Rev 1997; 25: 47–58CrossRef
27.
Zurück zum Zitat Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm 2000 Mar; 50: 161–77PubMedCrossRef Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm 2000 Mar; 50: 161–77PubMedCrossRef
28.
Zurück zum Zitat Björk M, Wettergren B. Scopolamine patches cause hallucinations [in Swedish]. Läkartidningen 1995; 92: 638PubMed Björk M, Wettergren B. Scopolamine patches cause hallucinations [in Swedish]. Läkartidningen 1995; 92: 638PubMed
29.
Zurück zum Zitat Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperacitivity disorder in children. Drugs 2006; 66 (8): 1117–26PubMedCrossRef Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperacitivity disorder in children. Drugs 2006; 66 (8): 1117–26PubMedCrossRef
30.
Zurück zum Zitat Berger WE. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Del 2005; 2 (6): 965–80CrossRef Berger WE. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Del 2005; 2 (6): 965–80CrossRef
31.
Zurück zum Zitat Schüepp K, Jauernig J, Janssens H, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med 2005; 18 (2): 225–35PubMedCrossRef Schüepp K, Jauernig J, Janssens H, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med 2005; 18 (2): 225–35PubMedCrossRef
32.
Zurück zum Zitat Janssens H, De Jongste J, Hop W, et al. Extra-fine particles improve lung delivery of inhaled steroids in infants. Chest 2003; 123: 2083–8PubMedCrossRef Janssens H, De Jongste J, Hop W, et al. Extra-fine particles improve lung delivery of inhaled steroids in infants. Chest 2003; 123: 2083–8PubMedCrossRef
33.
Zurück zum Zitat Dolovich M. Influence of inspiratory flow rate, particle size and airway caliber in aerosolized drug delivery to the lung. Respir Care 2000; 45: 597–608PubMed Dolovich M. Influence of inspiratory flow rate, particle size and airway caliber in aerosolized drug delivery to the lung. Respir Care 2000; 45: 597–608PubMed
34.
Zurück zum Zitat Geller D, Eigen H, Fiel S, et al. Effect of smaller droplet size of Dornase Alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 1998; 25: 83–7PubMedCrossRef Geller D, Eigen H, Fiel S, et al. Effect of smaller droplet size of Dornase Alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 1998; 25: 83–7PubMedCrossRef
35.
Zurück zum Zitat Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 1996; 21: 276–81PubMedCrossRef Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 1996; 21: 276–81PubMedCrossRef
36.
Zurück zum Zitat Schüepp K, Straub D, Möller A, et al. Deposition of aerosols in infants and children. J Aerosol Med 2004; 17 (2): 153–6PubMedCrossRef Schüepp K, Straub D, Möller A, et al. Deposition of aerosols in infants and children. J Aerosol Med 2004; 17 (2): 153–6PubMedCrossRef
37.
Zurück zum Zitat Everard M. Inhaler devices in infants and children: challenges and solutions. J Aerosol Med 2004; 17 (2): 186–95PubMedCrossRef Everard M. Inhaler devices in infants and children: challenges and solutions. J Aerosol Med 2004; 17 (2): 186–95PubMedCrossRef
38.
Zurück zum Zitat Devadason S, Everard M, Macerlean C, et al. Lung deposition from the Turbohaler in children with cystic fibrosis. Eur Respir J 1997; 10: 2023–8PubMedCrossRef Devadason S, Everard M, Macerlean C, et al. Lung deposition from the Turbohaler in children with cystic fibrosis. Eur Respir J 1997; 10: 2023–8PubMedCrossRef
39.
Zurück zum Zitat Wildhaber J, Dore N, Wilson J, et al. Inhalation therapy in asthma: nebulizer or pressured metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28–33PubMedCrossRef Wildhaber J, Dore N, Wilson J, et al. Inhalation therapy in asthma: nebulizer or pressured metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28–33PubMedCrossRef
40.
Zurück zum Zitat Diot P, Palmer A, Smaldone A, et al. RhD-Nase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1662–8PubMed Diot P, Palmer A, Smaldone A, et al. RhD-Nase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1662–8PubMed
41.
Zurück zum Zitat Biggart E, Bush A. Antiasthmatic drug delivery in children. Pediatr Drugs 2002; 4 (2): 85–93 Biggart E, Bush A. Antiasthmatic drug delivery in children. Pediatr Drugs 2002; 4 (2): 85–93
42.
Zurück zum Zitat Collis G, Cole C, Le Souef P. Dilution of nebulized aerosols by air entrainment in children. Lancet 1990; 336: 341–3PubMedCrossRef Collis G, Cole C, Le Souef P. Dilution of nebulized aerosols by air entrainment in children. Lancet 1990; 336: 341–3PubMedCrossRef
43.
Zurück zum Zitat Crompton G. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982; 63: 101–42 Crompton G. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982; 63: 101–42
44.
Zurück zum Zitat Kamps A, Van Ewijk B, Roorda R, et al. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000; 29: 39–42PubMedCrossRef Kamps A, Van Ewijk B, Roorda R, et al. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000; 29: 39–42PubMedCrossRef
45.
Zurück zum Zitat Everard M. Designing inhalers for children in the 21st century. In: Drug delivery 2007. London: Touch Briefings, 2007 Jun: 9–12 Everard M. Designing inhalers for children in the 21st century. In: Drug delivery 2007. London: Touch Briefings, 2007 Jun: 9–12
46.
Zurück zum Zitat Tuleu C. Paediatric formulations in practice. In: Costello I, Long P, Wong I, et al., editors. Paediatric drug handling. London: Pharmaceutical Press, 2007: 70–2 Tuleu C. Paediatric formulations in practice. In: Costello I, Long P, Wong I, et al., editors. Paediatric drug handling. London: Pharmaceutical Press, 2007: 70–2
47.
Zurück zum Zitat Breitkreutz J, Tuleu C, Solomonidou D. Paediatric formulations. In: Rose K, van den Anker J, editors. Guide to paediatric clinical research. Basel: A S. Karger, 2007 Breitkreutz J, Tuleu C, Solomonidou D. Paediatric formulations. In: Rose K, van den Anker J, editors. Guide to paediatric clinical research. Basel: A S. Karger, 2007
48.
Zurück zum Zitat Wirtz V, Taxis K, Barber N. An observational study of intravenous medication errors in the United Kingdom and in Germany. Pharm World Sci 2003; 25: 104–11PubMedCrossRef Wirtz V, Taxis K, Barber N. An observational study of intravenous medication errors in the United Kingdom and in Germany. Pharm World Sci 2003; 25: 104–11PubMedCrossRef
49.
Zurück zum Zitat Taxis K, Barber N. Incidence and severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol 2004; 59: 815–7PubMedCrossRef Taxis K, Barber N. Incidence and severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol 2004; 59: 815–7PubMedCrossRef
50.
Zurück zum Zitat Allegaert K, Anderson BJ, Vrancken M. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates. Paediatr Perinat Drug Ther 2006; 7 (2): 59–63CrossRef Allegaert K, Anderson BJ, Vrancken M. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates. Paediatr Perinat Drug Ther 2006; 7 (2): 59–63CrossRef
51.
Zurück zum Zitat Wurdack W, Kittlaus A, Pecar R, et al. Release of components from primary package materials and their migration into drug and nutrition solutions [in German]. Krankenhauspharmazie 2006; 27: 334–9 Wurdack W, Kittlaus A, Pecar R, et al. Release of components from primary package materials and their migration into drug and nutrition solutions [in German]. Krankenhauspharmazie 2006; 27: 334–9
52.
Zurück zum Zitat Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr Respir Rev 2007; 8: 62–6PubMedCrossRef Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr Respir Rev 2007; 8: 62–6PubMedCrossRef
Metadaten
Titel
Improving Drug Delivery in Paediatric Medicine
verfasst von
Julia Krause
Dr Jörg Breitkreutz
Publikationsdatum
01.01.2008
Verlag
Springer International Publishing
Erschienen in
Pharmaceutical Medicine / Ausgabe 1/2008
Print ISSN: 1178-2595
Elektronische ISSN: 1179-1993
DOI
https://doi.org/10.1007/BF03256681

Weitere Artikel der Ausgabe 1/2008

Pharmaceutical Medicine 1/2008 Zur Ausgabe

Review Article

Dose Estimation

Update

Forum